Iradimed Corp’s Quiet Period Set To Expire on August 25th (NASDAQ:IRMD)
Iradimed Corp’s (NASDAQ:IRMD) quiet period is set to expire on Monday, August 25th. Iradimed Corp had issued 2,016,000 shares in its IPO on July 16th, American Banking News reports. The total size of the offering was $12,600,000 based on an initial share price of $6.25. During the company’s quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
Separately, analysts at Roth Capital initiated coverage on shares of Iradimed Corp in a research note on Monday, August 11th. They set a “buy” rating and a $14.00 price target on the stock.
Shares of Iradimed Corp (NASDAQ:IRMD) traded down 0.55% on Wednesday, hitting $10.92. 316 shares of the company’s stock traded hands. Iradimed Corp has a one year low of $7.94 and a one year high of $13.60. The stock has a 50-day moving average of $9.74 and a 200-day moving average of $9.74. The company has a market cap of $76.4 million and a P/E ratio of 43.75.
Iradimed Corp (NASDAQ:IRMD) last announced its earnings results on Tuesday, August 12th. The company reported $0.13 EPS for the quarter. The company had revenue of $4.70 million for the quarter, compared to the consensus estimate of $2.80 million. On average, analysts predict that Iradimed Corp will post $0.35 earnings per share for the current fiscal year.
iRadimed Corporation is a provider of non-magnetic intravenous (NASDAQ:IRMD) infusion pump systems that are safe for use during magnetic resonance imaging (MRI) procedures.
Receive News & Ratings for Iradimed Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.